Premium
Induction of antibodies against seasonal allergy in foals by a novel peptide
Author(s) -
Venugopal Changaram S.,
Prayaga Sudhirdas,
Holmes Earnestine,
Lyle Sara
Publication year - 2013
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.27.1_supplement.895.1
Subject(s) - keyhole limpet hemocyanin , peptide , antibody , medicine , immunology , immunoglobulin e , allergy , chemistry , biochemistry
Equine recurrent airway obstruction (RAO) is a type‐I immediate hypersensitivity response involving reaginic antibodies (IgE and IgG). Normally horses are protected from airway inflammation by secretoglobulins secreted by Clara Cells in airway epithelium. A peptide with 21 amino acids was developed from equine Clara Cell protein (CC10) and the objective of the study was to investigate the peptide's ability to induce antibody production in Shetland pony foals. The peptide has homology to common environmental allergens. The study was approved by IACUC of LSU. The age of the foals ranged from 4–6 months. The peptide was covalently conjugated with a large carrier protein, Keyhole Limpet Hemocyanin (KLH) and administered to one foal subcutaneously at a dose of 0.1 mg/kg body weight. Two more foals were given the conjugated peptide with an equal volume of Freund's incomplete adjuvant (IFA). Five ml of blood was collected before the injection of the peptide and post injection weekly for 42 days. The results of blood analysis indicated that the antibody titer increased exponentially with time in foals that received conjugated peptide with IFA. This finding suggests that the peptide has the potential to be used as a vaccine against seasonal allergic diseases such as RAO. The study was supported by funding from Equine Health Studies Program of LSU‐SVM.